Skip to main content

Variantyx, FDNA Integrate Whole Genome Tests With Phenotyping Applications

NEW YORK (GenomeWeb) – Variantyx said today that it is integrating its clinical whole genome testing pipeline with FDNA’s Face2Gene clinical suite of phenotyping applications.

The integration enables clinicians to send information directly to Variantyx about the phenotypes, syndromes, and genes that correlate with a patient’s facial and clinical analysis. This would speed analysis and improve upon variant interpretation, Variantyx said.

Variantyx provides end-to-end clinical diagnostic services for rare genetic disorders based on whole genome sequencing, using its proprietary Genomic Intelligence platform.

FDNA offers a suite of phenotyping applications called Face2Gene that uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses, based on a database of more than 10,000 rare disease syndromes.

Variantyx CEO Haim Neerman said in a statement that his firm's collaborative diagnostic approach, which leverages close interaction between the ordering clinician and the company's board-certified medical geneticists, "provides important input that shapes variant interpretation.”

“By integrating FDNA’s technology within the Variantyx Genomic Intelligence platform, "a more complete phenotypic picture is provided, helping prioritize genetic variants that may have otherwise been missed,” he said.